Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ali Muhammed Ali

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Reports of Biochemistry & Molecular Biology|June 29, 2022
Study of Antibacterial Chemical Substances and Molecular Investigation among Sulfamethoxazole-trimethoprim (SXT)-Resistant <i>Escherichia coli</i> IsolatesRuaa Ali Muhammed Ali, Jamal Mohammed Ridha Alshara, Nabil Salim Saaid Tuwaij, et al.
Diabetes Care|March 30, 2020
Combination Therapy With Canagliflozin Plus Liraglutide Exerts Additive Effect on Weight Loss, but Not on HbA<sub>1c</sub>, in Patients With Type 2 DiabetesAli Muhammed Ali, Robert Martinez, Hussein Al-Jobori, et al.
The Journal of Clinical Endocrinology and Metabolism|August 4, 2020
Improved Beta Cell Glucose Sensitivity Plays Predominant Role in the Decrease in HbA1c with Cana and Lira in T2DMAli Muhammed Ali, Andrea Mari, Robert Martinez, et al.
Diabetes|January 10, 2020
Evidence Against an Important Role of Plasma Insulin and Glucagon Concentrations in the Increase in EGP Caused by SGLT2 InhibitorsMariam Alatrach, Nitchakarn Laichuthai, Robert Martinez, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Reports of Biochemistry & Molecular Biology|June 29, 2022
Study of Antibacterial Chemical Substances and Molecular Investigation among Sulfamethoxazole-trimethoprim (SXT)-Resistant <i>Escherichia coli</i> IsolatesRuaa Ali Muhammed Ali, Jamal Mohammed Ridha Alshara, Nabil Salim Saaid Tuwaij, et al.
Diabetes Care|March 30, 2020
Combination Therapy With Canagliflozin Plus Liraglutide Exerts Additive Effect on Weight Loss, but Not on HbA<sub>1c</sub>, in Patients With Type 2 DiabetesAli Muhammed Ali, Robert Martinez, Hussein Al-Jobori, et al.
The Journal of Clinical Endocrinology and Metabolism|August 4, 2020
Improved Beta Cell Glucose Sensitivity Plays Predominant Role in the Decrease in HbA1c with Cana and Lira in T2DMAli Muhammed Ali, Andrea Mari, Robert Martinez, et al.
Diabetes|January 10, 2020
Evidence Against an Important Role of Plasma Insulin and Glucagon Concentrations in the Increase in EGP Caused by SGLT2 InhibitorsMariam Alatrach, Nitchakarn Laichuthai, Robert Martinez, et al.
Pageof 1